Exelixis (EXEL) Tmuɣli n wazal
Ṛṛbem n lḥedd$58.18Yettwalemmaḍ 25 Sep 2026 19:59 UTC
Beddel+0.41%
Asnulfu n AI: EXEL
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
Exelixis, Inc. is a biotechnology company specializing in the development of promising small-molecule drugs for the treatment of cancer and other serious diseases, including kidney disease, thyroid cancer, and advanced melanoma. The company also establishes strategic partnerships with other pharmaceutical and biotechnology firms.
